Holly K. Tabor, PhD and Aaron Goldenberg, PhD, MPH
Rare genetic disease research has something to teach precision medicine about addressing some patients’ limited access to treatment. Health disparities exacerbated by high costs and limited availability of drugs can, perhaps, be mitigated when patient activism accelerates drug development.
AMA J Ethics. 2018;20(9):E834-840. doi:
10.1001/amajethics.2018.834.
Rebekah Davis Reed, PhD, JD and Erik L. Antonsen, PhD, MD
Though the National Aeronautics and Space Administration’s collection of disaggregated genetic data for occupational surveillance and research raises numerous privacy concerns, the Genetic Information Nondiscrimination Act of 2008 allows genetic information to be used to develop personal pharmaceuticals.
AMA J Ethics. 2018;20(9):E849-856. doi:
10.1001/amajethics.2018.849.
The Holocaust and the racial hygiene doctrine that helped rationalize it still overshadow contemporary debates about using gene editing for disease prevention.
AMA J Ethics. 2021;23(1):E49-54. doi:
10.1001/amajethics.2021.49.
Madison L. Esposito and Michelle Kahn-John, PhD, RN
Most clinicians receive little training in integrating Native healing into allopathic practice, which undermines patients’ autonomy and cultural values.
AMA J Ethics. 2020;22(10):E837-844. doi:
10.1001/amajethics.2020.837.
Kelsey Mumford, Lin Fraser, EdD, and Gail Knudson, MD, MEd
While transgender health care has moved beyond “gender identity disorder” and “gender dysphoria” as mental illnesses, gender incongruence continues to be a source of oppression.
AMA J Ethics. 2023;25(6):E446-451. doi:
10.1001/amajethics.2023.446.
Zareen Zaidi, MD, PhD, Daniele Ölveczky, MD, MS, Nicole A. Perez, PhD, Paolo C. Martin, PhD, Andres Fernandez, MD, MSEd, Philicia Duncan, MD, and Hannah L. Anderson, MBA
This article canvasses ways to help trainees cultivate discernment and action in response to inequity.
AMA J Ethics. 2024;26(1):E12-20. doi:
10.1001/amajethics.2024.12.